Registry-listed formulations

Scopolamine Hydrobromide · mesh:M0019553

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Intravenous scopolamine hydrobromideRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
50%(1 trials)

Phase Distribution

Phase 1
1
50%
Phase 4
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 4Post-market surveillance
1(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(2)

Detailed Status

Completed2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (50.0%)
Phase 41 (50.0%)

Trials by Status

completed2100%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_4

Scopolamine Patch Pharmacokinetics in Healthy Adults

NCT03029650
completedphase_1

The Application of Spasmolytic in PCLE Examination of Superior Gastrointestinal Endoscope

NCT02811341

Clinical Trials (2)

Showing 2 of 2 trials
NCT03029650Phase 4

Scopolamine Patch Pharmacokinetics in Healthy Adults

Completed
NCT02811341Phase 1

The Application of Spasmolytic in PCLE Examination of Superior Gastrointestinal Endoscope

Completed

All 2 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
2

External References

ChEMBL
CHEMBL2251240